August 13, 2020 – New interim data from Phase 2 ACCURACY study of AL101 for the treatment of R/M ACC to be presented at ESMO 2020 – – On...

July 9, 2020 Published work highlights the preclinical development of BND-22, an anti-ILT2 multi-cell checkpoint inhibitor that enhances...

May 6, 2020 Elad Kedar, CEO of Orasis Pharmaceuticals shares his strategy for successfully completing a Phase 2b clinical study in...

July 21, 2020 Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for...

May 15, 2020 AS OPERATORS CONTINUE TO INVEST IN IMPROVED CONNECTIVITY AND PASSENGER EXPERIENCE ON THEIR METRO SYSTEMS, THEY INEVITABLY...